TSX · Drug Manufacturers - Specialty & Generic · CAD

HLS Therapeutics Inc. (HLS.TO) Stock Analysis

HLS Therapeutics Inc. (HLS.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

Last Updated: October 21, 2026

HLS.TO

CA$4.13

−CA$0.02 (−0.48%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HLS.TO with… →

HLS.TO Key Statistics

As of Oct 21, 2026

Trading

Open: CA$4.15
Previous Close: CA$4.15
Day's Range: 4.09–4.15
52-Week Range: 0.001–5.62
Volume: 13.10K
Beta: 0.76

Valuation

Market Cap: CA$127.76M
P/E Ratio: unprofitable
P/S ratio: 2.27
EPS (ttm): −0.37

Financials (FY)

Revenue (FY): CA$55.50M−1.98%
Net Income (FY): −CA$12.43M
Profit margin: −15.24%
Shares Outstanding: 30.94M
1-Year Return: −25.99%

Dividend and dates

Earnings Date: November 12, 2026
Avg Volume: 68.69K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, HLS.TO closed at CA$4.13, −25.99% over 1 year.

HLS Therapeutics Inc. (HLS.TO) has a market capitalization of CA$127.76M.

In fiscal 2025, HLS.TO reported revenue of CA$55.50M.

HLS.TO Stock Return by Calendar Year

HLS Therapeutics Inc. (HLS.TO) return since Mar 2018: what CA$10,000 became

1 year: CA$10,000 CA$7,401; −25.99%
5 years: CA$10,000 CA$2,105; −78.95%
Since Mar 2018: CA$10,000 CA$3,833; −61.67%

If you had invested CA$10,000 in HLS Therapeutics Inc. (HLS.TO) at the close on March 14, 2018, the earliest close on record here, it would have been worth CA$3,833 at the close on October 21, 2026: −61.67% in total, −10.55% a year, with dividends reinvested, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+76.29%−59.25%−14.32%

2018*20192020202120222023202420252026*

Year	Return
2026 (partial year)	−14.32%
2025	+22.65%
2024	−0.51%
2023	−59.25%
2022	−33.41%
2021	−15.74%
2020	−28.62%
2019	+76.29%
2018 (partial year)	+27.39%

As of October 21, 2026.

HLS.TO Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	CA$55.50M	−CA$12.43M	−22.4%
2024	CA$56.62M	−CA$19.66M	−34.7%
2023	CA$63.07M	−CA$27.53M	−43.6%
2022	CA$61.47M	−CA$23.60M	−38.4%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	CA$55.50M	CA$45.42M	−CA$4.11M	−CA$12.43M	−22.4%
2024	CA$56.62M	CA$47.62M	−CA$7.69M	−CA$19.66M	−34.7%
2023	CA$63.07M	CA$55.45M	−CA$10.35M	−CA$27.53M	−43.6%
2022	CA$61.47M	CA$56.49M	−CA$13.50M	−CA$23.60M	−38.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HLS.TO Dividend History

’19’20’21’22’23

CA$0.10−50.0% vs 2022

Dividends per share, 2023 · 2 payments

Year	Dividends per share	Payments	Change
2023	CA$0.10	2	−50.0%
2022	CA$0.20	4	+0.0%
2021	CA$0.20	4	+0.0%
2020	CA$0.20	4	+0.0%

Year	Dividends per share	Payments	Change
2023	CA$0.10	2	−50.0%
2022	CA$0.20	4	+0.0%
2021	CA$0.20	4	+0.0%
2020	CA$0.20	4	+0.0%
2019	CA$0.20	4	—

Most recent payment: CA$0.05 per share, ex-dividend April 27, 2023. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

HLS.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks

Metric	HLS.TO	Drug Manufacturers - Specialty & Generic median	vs median
P/S ratio	2.27	2.10	8% above
Profit margin	−15.24%	−8.14%	7.1 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

The market values HLS Therapeutics Inc. (HLS.TO) at CA$127.76M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 85.

The 52-week range on file runs from CA$0.001 to CA$5.62. The most recent close on file for HLS.TO is CA$4.13, dated October 21, 2026. That is −CA$0.02 (−0.48%) against the previous close. The latest close sits 412,900% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of CA$55.50M. That is −1.98% against the prior fiscal year, when revenue was CA$56.62M. The same year closed with a net loss of CA$12.43M. Profit margin runs at −15.24%. That is 7.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to −0.37.

Across the 4 fiscal years on file, revenue moves from CA$61.47M in 2022 to CA$55.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 2.27 times revenue. On price-to-sales that is 8.17% above the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year total return is −25.99%. Across 5 years the annualized return works out at −26.78%. The reported beta is 0.76. Annualized volatility over the trailing 8 years is 42.72%.

Growth & Income

The dividend record for HLS.TO runs through 2023. Dividends are recorded for 5 calendar years; 2023 shows 2 payments totalling CA$0.10 a share. The year before, 2022, totalled CA$0.20 a share.

Across the complete calendar years on file, 2019 returned +76.29% and 2023 returned −59.25%. Of the 7 complete calendar years on file, 2 finished higher. So far in 2026 the total return is −14.32%.

Peer Comparison

HLS Therapeutics Inc. (HLS.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
HLS Therapeutics Inc.	HLS.TO	CA$127.76M	—
Takeda Pharmaceutical Company Limited	TAK	$63.67B	—
Teva Pharmaceutical Industries Limited	TEVA	$47.37B	67.7
Haleon plc	HLN	$44.06B	20.5

Market caps are shown in each company's own trading currency, without conversion, and the peers are listed in order of these unconverted figures.

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. HLS Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

TEVA

Teva Pharmaceutical Industries Limited

$47.37B

HLN

Haleon plc

$44.06B

ZTS

Zoetis Inc.

$32.90B

UTHR

United Therapeutics Corporation

$24.17B

VTRS

Viatris Inc.

$21.19B

View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About HLS Therapeutics Inc.

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

Visit website →